Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 20 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 10822427

    Anti-CSPG4 fusions with interferon for the treatment of malignancy

    The Regents of the University of California · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  2. US 10813366

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  3. US 10815285

    Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  4. US 10815480

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  5. US 10815483

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted
  6. US 10808020

    Nuclease-mediated regulation of gene expression

    Sangamo Therapeutics, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  7. US 10799580

    Expression vector delivery system and use thereof for inducing an immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  8. US 10800833

    Co-stimulatory domains for use in genetically-modified cells

    Precision BioSciences, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  9. US 10799535

    Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted
  10. US 10792481

    Implantable drug delivery device

    Nano Precision Medical, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted
  11. US 10793862

    Compositions and methods for modulating growth hormone receptor expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted
  12. US 10793855

    Compositions for modulating expression of C9ORF72 antisense transcript

    Ionis Pharmaceuticals, Inc. · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted
  13. US 10793865

    Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions

    The Government of the United States of America, as represented by the Secretary of the Navy · Granted Oct 6, 2020 · Expires Oct 1, 2040

    granted
  14. US 10786435

    Composition for optical three-dimensional modeling

    KURARAY NORITAKE DENTAL INC. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  15. US 10788490

    Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits

    ST. JUDE MEDICAL, CARDIOLOGY DIVISION, INC. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted
  16. US 10781242

    Interleukin-2 fusion proteins and uses thereof

    Medicenna Therapeutics Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted
  17. US 10774333

    Modulators of PNPLA3 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  18. US 10774334

    Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  19. US 10772906

    Modulation of Factor 11 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  20. US 10760076

    Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion

    ProQR Therapeutics II B.V. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  21. US 10758595

    Treatment of retinitis pigmentosa using engineered meganucleases

    Precision BioSciences, Inc. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  22. US 10745702

    Compositions and methods for inhibiting expression of the LECT2 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  23. US 10745665

    Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

    Precision BioSciences, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted
  24. US 10745704

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted